Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10401636 | 0.98 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL15211959 | 0.87 | EPHX1 (0.57) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL20610580 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL12780602 | 0.84 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL30476766 | 0.84 | EPHX1 (0.63) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL15062093 | 0.83 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL10861078 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL16541245 | 0.80 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL21814500 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL16024869 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| EP-1126846-B1 | Use of a nicotine receptor agonist for the manufacture of a medicament for the treatment of obsessive compulsive disorder | CARLSSON A RESEARCH AB (SE) | 2003-08-06 | — | — | EP | claimed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| EP-4309582-A1 | BIO-ELECTRODE COMPOSITION, BIO-ELECTRODE, AND METHOD FOR MANUFACTURING THE SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-24 | — | — | EP | disclosed |
| EP-4306558-A1 | BIOELECTRODE, PRODUCTION METHOD FOR BIOELECTRODE, AND MEASUREMENT METHOD FOR BIOSIGNALS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-17 | — | — | EP | disclosed |
| EP-3984456-B1 | BIO-ELECTRODE COMPOSITION, BIO-ELECTRODE, METHOD FOR MANUFACTURING BIO-ELECTRODE, POLYMER COMPOUND, AND COMPOSITE | SHINETSU CHEMICAL CO (JP) | 2023-08-23 | — | — | EP | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022122035-A1 | COAGULATION FACTOR XIA INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海领泰生物医药科技有限公司 | 2022-06-16 | — | — | WO | disclosed |
| US-20180110768-A1 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS | PARKINSON'S INSTITUTE | 2018-04-26 | — | — | US | disclosed |
| US-20160235732-A1 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS | PARKINSON'S INSTITUTE | 2016-08-18 | — | — | US | disclosed |
| EP-1977746-B1 | Methods and compositions for reduction of side effects of therapeutic treatments | PARKINSON S INST (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | ANIONA APS (DK) | 2004-05-13 | — | — | US | disclosed |
| EP-1358177-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NeuroSearch A/S (DK) | 2003-11-05 | — | — | EP | disclosed |
| EP-1126846-B1 | Use of a nicotine receptor agonist for the manufacture of a medicament for the treatment of obsessive compulsive disorder | CARLSSON A RESEARCH AB (SE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | disclosed |
| EP-1126846-A1 | USE OF A NICOTINE RECEPTOR AGONIST IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER | A Carlsson Research AB (SE) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025783-A1 | USE OF A NICOTINE RECEPTOR AGONIST IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER | A CARLSSON RESEARCH AB (SE) | 2000-05-11 | — | — | WO | disclosed |
| EP-0137145-A1 | New camptothecin derivatives and process for preparing same | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110768-A1 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS | CHRNA5, CHRM3, CHRM5 | CHRNB2 14/4885CHRNA4 9/4885CHRM2 10/4885 |
| US-20160235732-A1 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS | CHRNA5, CHRM3, CHRM5 | CHRNB2 14/4885CHRNA4 9/4885CHRM2 10/4885 |
| US-20040092508-A1 | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | TAAR5, CHRNA5, CHRNA4 | CHRNB2 15/4885CHRNA4 3/4885CHRM2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.